↓ Skip to main content

A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2013
Altmetric Badge

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
5 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma
Published in
Journal for Immunotherapy of Cancer, November 2013
DOI 10.1186/2051-1426-1-s1-p132
Authors

Lee Krug, Alessandra di Pietro, Rajesh Narwal, Paul Robbins, Dongyue Fu, Aiman Shalabi, Ramy Ibrahim, Luana Calabro, Hedy Kindler

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 40%
Student > Doctoral Student 2 40%
Student > Postgraduate 1 20%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 1 20%
Biochemistry, Genetics and Molecular Biology 1 20%
Nursing and Health Professions 1 20%
Agricultural and Biological Sciences 1 20%
Unknown 1 20%